Telix Pharmaceuticals

Telix Pharmaceuticals ROA

The Return on Assets (ROA) of Telix Pharmaceuticals (TLX.AX) as of Nov 22, 2026 is -0.61 %. In the previous year, Return on Assets (ROA) was 3.58 % — a change of -117.09% (lower).

ROA

-0.61 %

YoY

-117.09%

Last updated:

In 2025, Telix Pharmaceuticals's return on assets (ROA) was -0.61 %, a -117.09% increase from the 3.58 % ROA in the previous year.

The Telix Pharmaceuticals ROA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROA
Date
ROA
Jan 1, 2018
-18.03 USD
Jan 1, 2019
-27.16 USD
Jan 1, 2020
-28.44 USD
Jan 1, 2021
-73.32 USD
Jan 1, 2022
-40.76 USD
Jan 1, 2023
1.52 USD
Jan 1, 2024
3.58 USD
Jan 1, 2025
-0.61 USD
The Telix Pharmaceuticals ROA history
YEARROAYoY
-0.61 %-117.09%
3.58 %+136.02%
1.52 %-103.72%
-40.76 %-44.41%
-73.32 %+157.77%
-28.44 %+4.72%
-27.16 %+50.64%
-18.03 %+44.45%
-12.48 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Telix Pharmaceuticals Stock analysis

What does Telix Pharmaceuticals do? Telix Pharmaceuticals Ltd. is a leading biopharmaceutical company specializing in the development of diagnostic and therapeutic solutions that work at the molecular level. The company's activities span across Europe, North America, and the Asia-Pacific region. Telix was formed through the merger of two Australian companies - Advanced Nuclear Medicine Ingredients (ANMI) and Radiopharmaceuticals Pty Ltd. The company's business model is based on translational medicine and it works closely with academic research groups and international partners to develop products and technologies aligned with the latest medical research and scientific knowledge. Telix has two main business divisions: Imaging and Therapy. The Imaging division focuses on the development of diagnostic radiopharmaceuticals for cancer and inflammation imaging, while the Therapy division concentrates on the development of radiopharmaceuticals for the treatment of cancer and other chronic diseases. The company offers a wide portfolio of products and solutions tailored to diseases of the nervous and immune systems, as well as to cancer diagnosis and treatment. These include the Prostate-Specific Membrane Antigen (PSMA)-targeting technology, which has the potential to significantly improve the early diagnosis and progression of prostate cancer, radiopharmaceuticals for bone imaging to enhance the diagnosis of bone metastases and other bone diseases, and radiopharmaceuticals for cancer therapy that show promising results in precision tumor treatment. Telix Pharmaceuticals aims to improve the diagnosis, treatment, and quality of life for patients with chronic diseases through its innovative products, strong network of partners, and commitment to entrepreneurial excellence. Telix Pharmaceuticals is one of the most popular companies on Eulerpool.

ROA Details

Understanding Telix Pharmaceuticals's Return on Assets (ROA)

Telix Pharmaceuticals's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Telix Pharmaceuticals's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Telix Pharmaceuticals's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Telix Pharmaceuticals’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Telix Pharmaceuticals stock

Return on Assets (ROA) of Telix Pharmaceuticals is -0.61 % in 2025.

Return on Assets (ROA) of Telix Pharmaceuticals changed from 3.58 % to -0.61 %, representing a -117.09% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) Telix Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s Telix Pharmaceuticals with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Telix Pharmaceuticals

All Key Metrics — Telix Pharmaceuticals